The award, which was in collaboration with the Renaissance School of Medicine, was received from the NY State Centre of Biotechnology at Stony Brook University.
On 24th July (2019), the Centre of Biotechnology at Stony Brook University announced it will support further development of CVD’s project for ‘c-VACNT™ material bio-interaction studies.’
“I’m excited to continue to investigate the potential of c-VACNT™ – structures for a broad range of medical applications,” said Dr. Srinivas Pentyala, Professor & Director of Translational Research at Stony Brook University.
“In particular, we will be investigating if the significant performance gains demonstrated by CVD’s Application Laboratory with water for oxygen/deoxygenation will also translate to venous blood oxygenation and carbon dioxide removal under ISO 719 test conditions as recommended by the FDA.
“We are excited to work together with the Renaissance School of Medicine to investigate the ECMO product and other medical potential of our c-VACNT™ material platform,” said Leonard Rosenbaum, President and CEO of CVD.
“Continued innovation in nanotechnology applications can lead to advanced medical products capable of ‘improving quality of life’ for the end user – in this case the patient.”
The collaboration will further support continued development of CVD’s advanced carbon-based fluid reactors which it first announced in November (2018).